Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 5/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7116055 | 0.92 | TAS1R3 (0.40) | TAS1R3TAS1R1TAS1R2CHRNA7DRD4 | |
| SCHEMBL7116435 | 0.86 | GRM5 (0.39) | TAS1R3TAS1R1TAS1R2GRM5 | |
| SCHEMBL7115114 | 0.86 | GRM5 (0.37) | GRM5 | |
| SCHEMBL7120687 | 0.85 | KDM2B (0.39) | GRM5 | |
| SCHEMBL7124744 | 0.84 | DRD4 (0.39) | DRD4GRM5 | |
| SCHEMBL7126777 | 0.84 | SLC9A1 (0.42) | CHRNA7DRD4GRM5 | |
| SCHEMBL6101324 | 0.84 | CYP2C9 (0.37) | CHRNA7GRM5 | |
| SCHEMBL7120585 | 0.84 | SLC6A3 (0.38) | CHRNA7GRM5 | |
| SCHEMBL6099256 | 0.84 | SSTR3 (0.40) | TAS1R3TAS1R1TAS1R2GRM5 | |
| SCHEMBL6100743 | 0.83 | SLC6A2 (0.34) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | claimed |
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | CYP7B1, UGT2B7, CYP1B1 | TAS1R3 4742/4885TAS1R1 4566/4885TAS1R2 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.